GEORGE CARRUM to Treatment Outcome
This is a "connection" page, showing publications GEORGE CARRUM has written about Treatment Outcome.
Connection Strength
0.185
-
Rituximab responsive refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006 Nov; 12(11):1201-2.
Score: 0.020
-
Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant. 2006 Mar; 37(6):547-52.
Score: 0.020
-
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
Score: 0.012
-
In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
Score: 0.012
-
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
Score: 0.011
-
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
Score: 0.011
-
Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2017 07; 17(7):408-414.
Score: 0.011
-
Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 12; 16(12):672-678.
Score: 0.010
-
Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
Score: 0.010
-
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25.
Score: 0.008
-
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
Score: 0.008
-
Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22.
Score: 0.008
-
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transplant. 2013 Nov; 48(11):1444-9.
Score: 0.008
-
Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2012 Oct; 18(10):1471-8.
Score: 0.008
-
Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol. 2011 Apr; 153(1):76-82.
Score: 0.007
-
Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010 Apr; 51(4):664-70.
Score: 0.006
-
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45.
Score: 0.005
-
Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84.
Score: 0.005
-
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6916-23.
Score: 0.005